Go to Dr. Arun K. Kalra Resume Go to Dr. Henry Tsai Resume Go to Dr. Varun Gupta Resume Go to Dr. Iliana Popescu Resume
Desert Cancer Care, Inc.
39000 Bob Hope Dr.,
Eisenhower Medical Center
Uihlein Bldg., Ste. 201
Rancho Mirage, CA  92270
Affiliating Institutions :
Eisenhower Medical Center
39000 Bob Hope Dr.,
Rancho Mirage, CA  92270
Medical School and Internship
Dayanand Medical College and Hospital
Punjab University, India
Internal Medicine Residency
Long Island College Hospital
State University of New York
Medical Oncology Fellowship
North Shore University Hospital
NYU School of Medicine
Board Certification:
Diplomate Medical Oncology, American Board of Internal Medicine
Particular interest in Lung, Prostate Cancers and GI Cancers.
Positions and Appointments:
2005 - Current
Desert Cancer Care, Inc.
Uihlein Bldg, #201
Eisenhower Medical Center Campus
39700 Bob Hope Drive
Rancho Mirage, CA 92270
2004 - 2005
Cancer and Blood Institute of the Desert,
Rancho Mirage, CA  92270
2000 - 2004
Medical Oncology
Morongo Medical Group
South Carolina
Honors and Awards:
. Chair, Section of Oncology
   Eisenhower Medical Center
. Chief Fellow, Hematology/Oncology
   North Shore Hospital, NY
.  Assistant Chief Resident Department of  Medicine
   Long Island College Hospital, NY
.  Awarded Best Graduating Resident
   Department of Medicine Long Island  College Hospital, NY
.  National Scholarship through Medical School
. American College of Physicians
. American Society of Clinical Oncology
  • Radiation therapy in cancer patients 80 years of age and older Am J Clin Oncol 2000 Oct; 23(5): 526-30
  • Liver dysfunction after high-dose chemotherapy and role of histologic diagnosis Poster presented at ASCO 2000.
  • Novel chemotherapy agents, The Chemotherapy Source Book,  editor M. Perry, 2001.
  • Letter to Editors:  Harrison’s Principles of Internal Medicine.  Comment on CDC Classification of AIDS
Research Experience:
ASCO 2010 Meeting
A phase ll study of a modified pegylated liposomal doxorubicin (PLD), bortezomid, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM).
Sub-Investigator - Novartis Pharmaceuticals Corp: A prospective, Randomized, Multi-Center, 3 arm of the continued efficacy and  safety of Zometa in patients with documented bone metastases from Breast cancer.  Protocol #CZOL446E2352
Principal-Investigator - Amgen Protocol# 20050154:  Phase 2,
Randomized, Double Blind, Placebo-Controlled Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Chemotherapy-Induced Thrombocytopenia In Subject with Advanced Non-Small Cell
Lung Cancer Already Receiving Gemcitabine and Platinum.
Sub-Investigator – GPC Biotech Inc.: Protocol # SAT3-06-04 Expanded Access  Study of Satraplatin Plus Prednisone in Patients with Hormone Refratory Prostate Cancer Previously Treated with Unlimited Cytotoxic Chemotherapy.
Principal-Investigator for Millennium Pharma., : Protocol # C05009:
Phase IIIB, randomized study of three treatment regimens in subjects with previously untreated Multpile Myeloma who are not considered candidates High Dose Chemotherapy and Autologous Stem Cell Transplatation.  Velcade, Thalomide & Dexamethasone (VTD) vs. Velcade and Dexamethasone (VD)
Vs. Velcade, Melphalan, and Prednisone (VMP).
Sub-Investigator – NSABP-B-42:  A Clinical Trial to Determine the Efficacy o Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Follow by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer.